Side-by-side · Research reference

CrystagenvsMGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-StrongHUMAN-REVIEWED14/55 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

MGF

IGF-1Ec Splice Variant · Muscle-Specific

IGF-1EcSplice variantArmakolas 2016

24-AASynthetic E-domain

Animal onlyHuman evidence

SQ · Research context only

01Mechanism of Action

Parameter

Crystagen

MGF

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Satellite cells (Pax7+) in skeletal muscleMoore 2018

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Satellite cell proliferation, myoblast differentiation, muscle fiber repair

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

—

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016 Vassilakos 2017

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

MGF

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

Animal models + in vitro only

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

—

Duration

Unknown — chronic administration presumed in animal models

—

Half-life

Not reported

—

Synthetic peptide

—

24-amino-acid E-domain sequence

Corresponds to human IGF-1Ec exons 4-6 region.

Rodent cardiac model

—

200 μg/kg via peptide-eluting microstructures

Post-MI injection; improved ejection fraction by 8 weeks.

Acute delivery (mouse MI)

—

Single bolus within 12 hrs post-infarctionShioura 2014

Delayed decompensation; no human protocol established.

Human evidence

—

None — no published clinical trials

All dosing extrapolated from animal models.

Detection in doping

—

Full-length MGF detected via LC-MS in illicit productsThevis 2014

WADA-prohibited since 2005; no therapeutic indication.

04Side Effects & Safety

Parameter

Crystagen

MGF

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

None — no clinical trials published

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Theoretical IGF-1 axis risk

—

Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)

Tumor promotion

—

IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer

Antibody development

—

Unknown — no longitudinal human exposure data

Local injection reaction

—

Presumed similar to other peptides (erythema, induration) — no direct evidence

Dysregulated expression with age

—

Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

MGF

·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
·No established therapeutic use — investigational only

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

MGF

·Family history of IGF-1-axis malignancies
·Use outside research setting

05Administration Protocol

Parameter

Crystagen

MGF

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015 Shioura 2014

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014

5. Research context only

—

Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

MGF

+ BPC-157

Multi-pathway

View BPC-157 →

MGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.

MGF: No established dose
BPC-157: 250–500 mcg SQ near injury site
Context: Animal models only
Primary benefit: Theoretical multi-tissue repair (muscle + tendon/ligament)

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.

MGF: No established dose
TB-500: 2–5 mg SQ weekly
Context: Animal models only
Primary benefit: Satellite cell activation + enhanced migration/angiogenesis